Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Red Cross Needs Type O Blood to Ease ShortageLess Pain, More Car Crashes: Legalized Marijuana a Mixed BagPolitical Controversies Could Fuel Bullying of LGBT Youth: StudyCBD -- It's Everywhere, But Does It Work?Brief EMS Training Saves Lives After Brain InjuryU.S. Improves Emergency Readiness, but Gaps PersistSlowing Climate Change Could Cut Health Costs, Save MoneyDispensing Opioid Antidote Without a Prescription Might Save LivesNot Just Opioids: Deaths Tied to Cocaine, Meth Are Soaring, TooMost Americans Hit Hard by Medical BillsYour Virtual Doctor Will 'See' You NowHigh Measles Rates Mean Kids, Adults Need Proper Vaccination: CDCMany Drivers Testing Positive for Marijuana, Even With Kids in CarMedicaid Could Save $2.6 Billion a Year With Dip in SmokingFDA Halts All Sales of Pelvic Mesh Products Tied to Injuries in WomenAnother Cost of the Opioid Epidemic: Billions of Dollars in Lost TaxesHealth Tip: Using an AEDNurse Practitioners Often Restricted From Prescribing Opioid TreatmentsForested Counties Have Lower Medicare Costs, Study FindsSimple CPR Doubles Survival OddsUninsured Get Short Shrift on Hospital StaysSpecial Bag Helps Patients Get Rid of Unused OpioidsHealth Tip: Responsibilities of Non-VaccinationDo Doctors Hounded by Malpractice Claims Just Shift Their Practice Elsewhere?Bans on Texting While Behind the Wheel Making Roads SaferColorado Sees Spike in ER Visits After Pot Made LegalMajor Medical Groups Call for Soda TaxesCould the U.S. Mail Deliver Better Colon Cancer Screening Rates?Opioid Rxs Decreasing, But Not for All DoctorsAfter Chinese Infant Gene-Editing Scandal, U.S. Health Officials Join Call for a BanAre 'Inactive' Ingredients in Your Drugs Really So Harmless?Need to Be Vaccinated? Try Your Local PharmacyBystanders Key to Cutting Cardiac Arrest DeathsMany Black Americans Live in Trauma Care 'Deserts'FDA Issues Asbestos Warning About Some Claire's Cosmetic ProductsFDA to Crack Down on Retailers That Keep Selling Tobacco to KidsBlood Donation by Teen Girls May Raise Anemia RiskNurses' Long Hours, Moonlighting Could Pose Patient Safety RiskBerkeley's Efforts Suggest Soda Taxes Do Cut Soda SalesOpioid Overdose Deaths Quadruple, Centered in 8 StatesPayments for Research Can Lead to Lies: StudyFDA Aims to Strengthen Sunscreen RulesAre Primary Care Doctors Prepared to Discuss Cancer Treatment?FDA Fell Short in Preventing Fentanyl Abuse Crisis, Report ClaimsPrimary Care Doctors Help Boost Life Spans, But More Are NeededMore Car Crashes Tied to Drivers High on OpioidsPoor Whites Bear the Brunt of U.S. Opioid Crisis, Studies FindFDA to Tighten Oversight of SupplementsAs U.S. Measles Outbreaks Spread, Why Does 'Anti-Vax' Movement Persist?Even Brief EMS Delay Can Cost Lives After Car Crash
Questions and AnswersVideosLinksBook Reviews
Related Topics

Health Insurance
Healthcare

FDA Warns Companies on Dangerous, Unapproved Stem Cell Treatments

HealthDay News
by By E.J. Mundell
HealthDay Reporter
Updated: Dec 21st 2018

new article illustration

FRIDAY, Dec. 21, 2018 (HealthDay News) -- After infections tied to unapproved stem cell treatments sent 12 people to hospital this past year, the U.S. Food and Drug Administration on Thursday issued a stern warning about the products.

"The letters we're issuing today to manufacturers, health care providers and clinics around the country are a reminder that there's a clear line between appropriate development of these products and practices that sidestep important regulatory controls needed to protect patients," FDA Commissioner Dr. Scott Gottlieb said in a statement.

At issue are stem cell treatments -- so-called "cell-based regenerative medicine." Because stem cells have the potential to generate any type of cell, these treatments have long been marketed as a cure-all for a range of illnesses.

Hundreds of clinics touting the unapproved treatments have sprung up across the United States.

However, shoddy oversight may have led some hopeful patients to be seriously harmed, not helped, by these therapies, the FDA said.

In a report published Thursday, researchers at the U.S. Centers for Disease Control and Prevention say 12 stem cell therapy patients developed infections so severe they required hospitalization, although none died. Seven of the cases occurred in Texas, four in Florida and one in Arizona, according to a team led by CDC investigator Kiran Perkins.

Between February and September of 2018, these patients sought the treatments for a variety of complaints, including chronic pain, joint or back pain, rheumatoid arthritis or osteoarthritis, and rotator cuff tears.

But potentially deadly infections, such as E. coli or enterococcus, quickly set in within the patients' joints or bloodstreams.

One patient required hospitalization for 58 days, another for 35, Perkins' team reported Dec. 20 in the CDC journal Morbidity and Mortality Weekly Report.

The CDC investigators say that in one Texas clinic implicated in cases there, the Enterococcus cloacae bacterium was found in all six vials containing the stem cell product used. Similar results were found in vials tested at other implicated clinics.

However, the source of the infections cited in the new report seemed to be the point of manufacture, not the clinics themselves.

The products covered by the new warning were processed by Genetech, based in San Diego, and distributed by Yorba Linda, Ca.-based Liveyon. None of the stem cell products were "FDA-approved or lawfully marketed," the CDC researchers said. Liveyon issued a recall of the implicated products in October.

The CDC researchers stressed that umbilical cord blood -- often used as the source of transplanted stem cells -- is extremely difficult to sterilize.

"Umbilical cord blood cannot be decontaminated after collection because there are currently no validated processes for sterilization, so manufacture of derived products must be highly controlled to prevent distribution of contaminated products," Perkins' team noted.

However, despite repeated warnings, "many companies, clinics, and clinicians continue to market products from various sources as treatment for orthopedic, neurologic and rheumatologic conditions without FDA approval," the team said. That poses "serious potential risks to patients," they added.

The new FDA warning letter is targeted to Genetech and Liveyon. The FDA says that in June its inspectors assessed conditions at Genetech's plant and "documented evidence of significant deviations" from standard guidelines on safe manufacture.

"These deviations pose a significant risk that the products may be contaminated with microorganisms or have other serious product quality defects," the FDA said.

Gottlieb said the FDA announcement issued Thursday is a final warning to companies before tougher enforcement.

"Time is running out for firms to come into compliance during our period of enforcement discretion," he said. "We'll be increasing our oversight related to cell-based regenerative medicine as part of our comprehensive plan to promote beneficial innovation while protecting patients."

More information

There's more on stem cell therapy at the U.S. National Center for Biotechnology Information.




Facebook

Amazon Smile

To quit smoking, call Connecticut QuitLine at 1-800-QUIT-NOW.

Children and Adult services are available now with no wait time.  Please contact HBH Intake Department at 860-548-0101, option 2.

 


powered by centersite dot net